Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile1 entries
2019
Goldman Sachs faces backlash over Helixmith outlook change
Public backlash
In October 2019, Goldman Sachs faced backlash from Helixmith and individual investors after changing its outlook on the Korean biopharmaceutical firm and sharply lowering its target price. Some investors suspected that the change was intended to facilitate short selling. The report presents this as a suspicion rather than an established finding, and no further details on the outcome or the parties involved are provided.
Source excerpt
Goldman Sachs has drawn a severe backlash from Helixmith and individual investors, after it flip-flopped on its outlook for the Korean biopharmaceutical firm, dragging down its target price sharply, according to industry officials, Monday.